ArticleBMC gastroenterology2017
Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014.
Article in BMC gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.Alimentary pharmacology & therapeutics · 2021Pooled it
- Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events.International journal of colorectal disease · 2020Pooled it
- National and state-level trends in digestive diseases in the United States, 1990 to 2021.Proceedings (Baylor University. Medical Center) · 2026Article
- Development of a healthcare utilisation index to compare patients worldwide: a cross-sectional study.BMC health services research · 2025Article
- Therapy Patterns and Surveillance Measures of Inflammatory Bowel Disease Patients beyond Disease-Related Hospitalization: A Claims-Based Cohort Study.Inflammatory intestinal diseases · 2022Article
- Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?Intestinal research · 2022Review
- Effectiveness of a 24-hour access outpatient clinic for patients with chronic conditions in hospital outpatient follow-up: a registry-based controlled cohort study of healthcare utilisation and mortality.Integrated healthcare journal · 2022Article
- Increasing Prevalence and Direct Health Care Cost of Inflammatory Bowel Disease Among Adults: A Population-Based Study From a Western Canadian Province.Journal of the Canadian Association of Gastroenterology · 2021Article
- Ideal Vial Size for Infliximab in the Treatment of Inflammatory Bowel Disease: An Analysis of Pharmaceutical Waste and Physician Opinions.Crohn's & colitis 360 · 2021Article
- Hospitalization and surgery rates in patients with inflammatory bowel disease in Brazil: a time-trend analysis.BMC gastroenterology · 2021Article
- Biologic therapy is associated with a mild decrease in the rate of hospitalizations in pediatric IBD.BMC pediatrics · 2021Article
- BMI in the lower and upper quartiles at diagnosis and at 1-year follow-up is significantly associated with higher risk of disease exacerbation in pediatric inflammatory bowel disease.European journal of pediatrics · 2021Article
- Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland.Advances in therapy · 2021Article
- Change in Colorectal Cancer Tests Submitted for Reimbursement in Switzerland 2012-2018: Evidence from Claims Data of a Large Insurance.International journal of public health · 2021Article
- Development of Machine Learning Model to Predict the 5-Year Risk of Starting Biologic Agents in Patients with Inflammatory Bowel Disease (IBD): K-CDM Network Study.Journal of clinical medicine · 2020Article
- Adaptation of TECCU App Based on Patients´ Perceptions for the Telemonitoring of Inflammatory Bowel Disease: A Qualitative Study Using Focus Groups.International journal of environmental research and public health · 2020Article
- Precision medicine in inflammatory bowel disease: concept, progress and challenges.F1000Research · 2020Review
- Rehospitalization rates, costs, and risk factors for inflammatory bowel disease: a 16-year nationwide study.Therapeutic advances in gastroenterology · 2020Article
- Predictors for poor outcome of hospitalized children with inflammatory bowel disease.European journal of pediatrics · 2020Article
- Comparative Incidence of Inflammatory Bowel Disease in Different Age Groups in the United States.Inflammatory bowel diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundReal-life data on inflammatory bowel disease (IBD) prevalence and costs are scarce. The aims of this study were to provide an overview of the prevalence, mortality, health care utilization and costs of IBD patients in Switzerland in the years 2010, 2012, and 2014.
methodsBased on claims data of the Helsana-Group, prevalence of IBD was assessed for 2010, 2012 and 2014. Mortality rates, costs (inpatient, outpatient, medication costs) and utilization (visits, hospitalizations) were compared between patients with and without IBD, and between IBD patients treated with and without biologics. Results were extrapolated to the Swiss general population using national census data. Multivariate linear regression was used to identify socio-demographic and regional factors influencing total costs.
resultsThe overall extrapolated prevalence rates of IBD were 0.32% in 2010, 0.38% in 2012, and 0.41% in 2014. Mortality rate didn't differ between the IBD and non-IBD population. Costs increased annually by 6% in IBD versus 2.4% in non-IBD subjects, which was solely due to increased outpatient costs. Almost one-fourth of IBD patients were hospitalized at least once a year. Costs were higher in IBD patients treated with biologics (OR = 3.98, CI: 3.72-4.27, p < 0.001) when compared to IBD patients without biologic therapies. Over 70% of the total costs in IBD patients treated with biologics were due to drug costs, compared with 28% in patients without use of biologic therapies, whereas inpatient costs didn't differ.
conclusionsThe prevalence of IBD seems to be increasing in Switzerland. Outpatient costs increased substantially, while no decrease in inpatient costs was found. Treatment of IBD is more and more based on biologic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.